Search
Harmony Biosciences Enrolls First Patient in Observational Study for Achondroplasia Treatment
4 week ago /
Read about 0 minute
Author：小编
Harmony Biosciences, a subsidiary of Harmony-B (02256.HK), based in Shanghai, has successfully enrolled the first patient in its observational study focused on the treatment of achondroplasia in children. The primary objective of this study is to gather essential baseline data for the development of ABSK061, a highly selective small molecule inhibitor targeting FGFR2/3. Notably, the Investigational New Drug (IND) application for ABSK061 has already received approval from China's National Medical Products Administration.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
